Lexaria Bioscience (LEXX) 10-Q 17 Jan 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Nov. 30, 2022	Jan. 17, 2023
Cover [Abstract]
Entity Registrant Name	LEXARIA BIOSCIENCE CORP.
Entity Central Index Key	0001348362
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Nov. 30, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		5,950,998
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	20-2000871
Entity Address Address Line 1	#100 – 740 McCurdy Road
Entity Address City Or Town	Kelowna
Entity Address State Or Province	BC
Entity Address Country	CA
Entity Address Postal Zip Code	V1X 2P7
City Area Code	1.250
Local Phone Number	765.6424
Security 12b Title	Common Stock, Par Value $0.001
Trading Symbol	LEXX
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Current
Cash	$ 4,533,063	$ 5,813,218
Marketable securities	269,707	347,335
Accounts receivable	286,322	201,784
Inventory	9,936	38,418
Prepaid expenses and deposit	260,342	576,761
Total Current Assets	5,359,370	6,977,516
Non-current assets, net
Right of use assets	42,340	52,444
Intellectual property	500,549	488,462
Property & equipment	311,221	315,505
Total Non-current Assets	854,110	856,411
TOTAL ASSETS	6,213,480	7,833,927
Current
Accounts payable and accrued liabilities	241,891	151,449
Lease payable	39,629	42,587
Total Current Liabilities	281,520	194,036
Long Term
Lease payable	0	7,401
Total Long Term Liabilities	0	7,401
TOTAL LIABILITIES	281,520	201,437
STOCKHOLDERS' EQUITY
Authorized 220,000,000 common voting shares with a par value of $0.001 per share Issued and outstanding: 5,950,998 common shares at November 30, 2022 and at August 31, 2022	5,951	5,951
Additional paid-in capital	47,110,257	47,041,481
Deficit	(40,854,472)	(39,098,528)
Equity attributable to shareholders of the Company	6,261,736	7,948,904
Non-controlling Interest	(329,776)	(316,414)
Total Stockholders' Equity	5,931,960	7,632,490
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 6,213,480	$ 7,833,927

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares	Nov. 30, 2022	Aug. 31, 2022
CONSOLIDATED BALANCE SHEET
Common stock, shares authorized	220,000,000	220,000,000
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares, issued	5,950,998	5,950,998
Common stock, shares, outstanding	5,950,998	5,950,998

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
Revenue	$ 101,476	$ 13,880
Cost of Goods Sold	15,795	5,570
Gross profit	85,681	8,310
Expenses
Research and development	829,489	458,709
Office and administration	1,025,498	1,553,083
Total operating expenses	1,854,987	2,011,792
Net loss	(1,769,306)	(2,003,482)
Net loss for the period	(1,769,306)	(2,003,482)
Net loss and comprehensive loss attributable to:
Common shareholders	(1,755,944)	(1,993,157)
Non-controlling interest	$ (13,362)	$ (10,325)
Basic and diluted income (loss) per share	$ (0.30)	$ (0.35)
Weighted average number of common shares outstanding
Basic and diluted	$ 5,950,998	$ 5,726,699

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Cash flows used in operating activities
Net loss and comprehensive loss	$ (1,769,306)	$ (2,003,482)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	68,776	408,544
Depreciation and amortization	24,730	27,930
Noncash right-of-use lease expense	10,104	9,385
Unrealized (gain) loss on marketable securities	77,628	340,417
Unrealized foreign exchange	0	(109)
Lease accretion	845	1,562
Change in operating assets and liabilities
Accounts receivable	(84,538)	(119,111)
Inventory	30,791	2,914
Prepaid expenses and deposits	316,419	82,030
Accounts payable and accrued liabilities	90,442	88,819
Due to related parties	0	(5,223)
Net cash used in by operating activities	(1,234,109)	(1,166,324)
Cash flows used in investing activities
Purchase of equipment	(20,500)	(42,375)
Intellectual property	(14,342)	(15,840)
Net cash (used in) provided by investing activities	(34,842)	(58,215)
Cash flows from financing activities
Lease Payments	(11,204)	(10,987)
Net cash used in by financing activities	(11,204)	(10,987)
Net change in cash for the period	(1,280,155)	(1,235,526)
Cash at beginning of period	5,813,218	10,917,797
Cash at end of period	4,533,063	9,682,271
Supplemental information of cash flows:
Income taxes paid in cash	$ 0	$ 0

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	COMMON STOCK	ADDITIONAL PAID-IN CAPITAL	DEFICIT	NCI
Balance, shares at Aug. 31, 2021		5,726,699
Balance, amount at Aug. 31, 2021	$ 13,063,552	$ 5,727	$ 45,089,114	$ (31,829,204)	$ (202,085)
Stock based compensation	408,544	0	408,544	0	0
Net loss	(1,993,157)	0	0	(1,993,157)	0
Non-controlling interest	(10,325)	$ 0	0	0	(10,325)
Balance, shares at Nov. 30, 2021		5,726,699
Balance, amount at Nov. 30, 2021	11,468,614	$ 5,727	45,497,658	(33,822,361)	(212,410)
Balance, shares at Aug. 31, 2022		5,950,998
Balance, amount at Aug. 31, 2022	7,948,904	$ 5,951	47,041,481	(39,098,528)	(316,414)
Stock based compensation	68,776	0	68,776	0	0
Net loss	(1,755,944)	0	0	(1,755,944)	0
Non-controlling interest	(13,362)	$ 0	0	0	(13,362)
Balance, shares at Nov. 30, 2022		5,950,998
Balance, amount at Nov. 30, 2022	$ 6,261,736	$ 5,951	$ 47,110,257	$ (40,854,472)	$ (329,776)

Nature of Business

Nature of Business	3 Months Ended
	Nov. 30, 2022
Nature of Business
Nature of Business	1. Nature of Business Lexaria Bioscience Corp. (“Lexaria”, “we”, “our” or the “Company”) is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“API”) using our proprietary DehydraTECH drug delivery technology. Revenues are generated from licensing contracts for the Company’s patented DehydraTECH technology based on the terms of use and defined geographic and licensing arrangements. We derive income from our third party contracted manufacturing of B2B DehydraTECH enhanced products made to customer specifications that are sold online and in-store in the US and Canada. We also perform contract services in R&D for customer specific formulations that are used in comparison testing to customers’ existing products. Going Concern Consideration The Company’s consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”) applicable to a going concern which assumes the Company will have sufficient funds to pay it operational, research and development and capital expenditures for a period of at least 12 months from the date this Report. Since inception, the Company has incurred significant operating and net losses. The losses attributable to shareholders were $7.4m, $4.2m and $4.1m for the years ended August 31, 2022, 2021 and 2020, respectively. As of November 30, 2022, we had an accumulated deficit of $40.9m. We expect to continue to incur significant operational expenses and net losses in the upcoming 12 months. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the stage and complexity of our R&D studies and corporate expenditures, additional revenues received from the licensing of our technology, if any, and the receipt of payments under any current or future collaborations we may enter into. The recurring losses from operations and negative cash flows from operations raise substantial doubt about the Company’s ability to continue as a going concern. As of November 30, 2022, the Company had cash of approximately $4.5m and carries no significant debt other than amounts payable in the short term. Also, on August 12, 2022, we entered into a sales agreement with Maxim Group LLC, (“Maxim”), pursuant to which we may offer and sell shares of our common stock with an aggregate offering price of up to $5,925,000 under the At-The-Market (“ATM”) Offering. The sales agreement provides that Maxim will be entitled to a sales commission equal to 3.0% of the gross sales price per share of all shares sold under the ATM Offering. As of January 17, 2023 we have not sold any shares under the ATM Offering. Based on our existing working capital and access to an ATM offering, as disclosed above management believes the Company has sufficient working capital to satisfy the Company’s estimated liquidity needs for the next 12 months. Because of the above factors, the Company believes that this alleviates the substantial doubt in connection with the Company's ability to continue as a going concern. However, there is no assurance that management’s plans will be successful due to the current economic climate in the United States and globally. Impacts of COVID-19 Pandemic The emergence of the COVID-19 pandemic in 2020 continues to present uncertainty and unforecastable new risks to the Company and its business plans. As of November 30, 2022, there has been no material impact on the Company’s financial position as a direct result of the pandemic. However, the Company has experienced some supply chain disruptions and shortages in the timely procurement of ingredients and supplies used in both our R&D activities and B2B production. Management views this situation as transitory but cannot predict the length of time it may take for these disruptions to dissipate or if there will be a significant economic effect on the Company’s operations. In the interim, it may cause delays in carrying out our research studies and in our production schedules. There may be further actions we must take that alter our operations, including those that may be required by federal, state, provincial, or local authorities, or that we determine are in the best interests of our employees and other third parties with which we do business. We do not know when it will become practical to relax or eliminate some or all these measures entirely. The economic effect of a prolonged pandemic is difficult to predict and could result in material financial impact in the Company’s future reporting periods.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Nov. 30, 2022
Significant Accounting Policies
Significant Accounting Policies	2. Significant Accounting Policies The significant accounting policies of the Company are consistent with those of our audited financial statements on Form 10-K for the year ended August 31, 2022.

Basis of Consolidation

Basis of Consolidation	3 Months Ended
	Nov. 30, 2022
Basis of Consolidation
Basis of Consolidation	3. Basis of Consolidation These interim consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries; Lexaria CanPharm ULC, Lexaria CanPharm Holdings Corp., PoViva Corp., Lexaria Hemp Corp., Kelowna Management Services Corp., and Lexaria Pharmaceutical Corp., and our 83.333% owned subsidiary Lexaria Nicotine LLC with the remaining 16.667% owned by Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc. All significant intercompany balances and transactions have been eliminated upon consolidation.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Nov. 30, 2022
Basis of Presentation
Basis of Presentation	4. Basis of Presentation The Company’s unaudited interim consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (US GAAP) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year or any subsequent period. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated annual financial statements and notes thereto included in our annual report filed on Form 10-K for the year ended August 31, 2022.

Recent Accounting Guidance

Recent Accounting Guidance	3 Months Ended
	Nov. 30, 2022
Recent Accounting Guidance
Recent Accounting Guidance	5. Recent Accounting Guidance Pronouncements Issued but Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

Estimates and Judgments

Estimates and Judgments	3 Months Ended
	Nov. 30, 2022
Estimates and Judgments
Estimates and Judgments	6. Estimates and Judgments The preparation of financial statements in conformity with U.S. GAAP requires us to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Some of the Company’s accounting policies require us to make subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. These accounting policies involve critical accounting estimates because they are particularly dependent on estimates and assumptions made by management about matters that are highly uncertain at the time the accounting estimates are made. Although we have used our best estimates based on facts and circumstances available to us at the time, different estimates reasonably could have been used. Changes in the accounting estimates used by the Company are reasonably likely to occur from time to time, which may have a material effect on the presentation of financial condition and results of operations. The Company reviews these estimates, judgments, and assumptions periodically and reflect the effects of revisions in the period in which they are deemed to be necessary. Although we believe that these estimates are reasonable actual results could differ. In preparing these unaudited interim consolidated financial statements, the significant judgments made by management in applying the Company’s accounting policies and the key sources of estimation uncertainty were the same as those applied to the audited consolidated financial statements for the year ended August 31, 2022.

Marketable Securities

Marketable Securities	3 Months Ended
	Nov. 30, 2022
Marketable Securities
Marketable Securities	7. Marketable Securities The components of Marketable Securities were as follows: Cost Basis $ Unrealized Gains $ Unrealized Losses $ Fair Value $ August 31, 2021 1,037,025 16,243 (219,427 ) 833,841 Common stock 278,107 118,196 (882,809 ) (486,506 ) August 31, 2022 1,315,132 134,439 (1,102,236 ) 347,335 Common stock - - (77,628 ) (77,628 ) November 30, 2022 1,315,132 134,439 (1,179,864 ) 269,707 Marketable securities represented the common shares of Hill Street Beverage Company Inc. held by Lexaria. Unrealized losses from common stock are due to market price movements. In management’s opinion based on the evaluation of available information at the quarter ended November 30, 2022, unrealized losses represent temporary impairments.

Accounts Receivables

Accounts Receivables	3 Months Ended
	Nov. 30, 2022
Accounts Receivables
Accounts Receivables	8. Accounts Receivables Accounts receivable at November 30, 2022 and August 31, 2022 consist of the following: November 30, August 31, 2022 2022 $ $ Trade and deposits 137,041 80,374 Territory license fees 100,683 37,248 Sales tax 48,598 84,162 286,322 201,784

Inventory

Inventory	3 Months Ended
	Nov. 30, 2022
Inventory
Inventory	9. Inventory Inventory at November 30, 2022 and August 31, 2022 consist of the following: November 30, August 31, 2022 2022 $ $ Raw materials 9,936 38,418 During the three month period ended November 30, 2022, inventory valued at $25,243 was expensed to research and development.

Prepaid Expenses and Deposits

Prepaid Expenses and Deposits	3 Months Ended
	Nov. 30, 2022
Prepaid Expenses and Deposits
Prepaid Expenses and Deposits	10. Prepaid Expenses and Deposits Prepaid expenses consist of the following at November 30, 2022, and August 31, 2022: November 30, August 31, 2022 2022 $ $ Advertising & conferences 74,656 359,863 Legal fees 25,000 25,000 License, filing fees, dues 3,750 15,000 Office & insurance 60,901 80,863 Capital financing 96,035 96,035 260,342 576,761

Intellectual Property, net

Intellectual Property, net	3 Months Ended
	Nov. 30, 2022
Intellectual Property, net
Intellectual Property	11. Intellectual Property, net The following is a list of US capitalized patents held by the Company: Issued Patent # Patent Certificate Grant Date Patent Family US 9,474,725 B1 10/25/2016 Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof US 9,839,612 B2 12/12/2017 US 9,972,680 B2 05/15/2018 US 9,974,739 B2 05/22/2018 US 10,084,044 B2 09/25/2018 US 10,103,225 B2 10/16/2018 US 10,381,440 08/13/2019 US 10,374,036 08/06/2019 US 10,756,180 08/25/2020 US 11,311,559 04/26/2022 Compositions and Methods for Enhanced Delivery of Antiviral Agents A continuity schedule for capitalized patents is presented below: November 30, August 31, 2022 2022 $ $ Balance – beginning 488,462 364,623 Addition 14,342 131,448 Amortization (2,255 ) (7,609 ) Balance – ending 500,549 488,462 Patents are amortized over their 20 year legal life.

Property and Equipment, net

Property and Equipment, net	3 Months Ended
	Nov. 30, 2022
Property and Equipment, net
Property & Equipment, net	12. Property & Equipment, net Three Months Ended November 30, 2022 Cost Period Amortization Additions Accumulated Amortization Net Balance November 30, 2022 $ $ $ $ $ Leasehold improvements 259,981 (13,509 ) - (208,195 ) 51,786 Computers 70,781 (1,183 ) - (62,607 ) 8,174 Furniture fixtures & equipment 31,126 (1,604 ) - (24,442 ) 6,684 Lab equipment 333,675 (8,616 ) 20,500 (109,598 ) 244,577 695,563 (24,912 ) 20,500 (404,842 ) 311,221 Year Ended August 31, 2022 Cost Period Amortization Disposal Accumulated Amortization Net Balance August 31, 2022 $ $ $ $ $ Leasehold improvements 259,981 (54,037 ) - (194,685 ) 65,296 Computers 63,964 (9,874 ) 6,817 (61,424 ) 9,357 Furniture fixtures & equipment 31,126 (6,417 ) - (22,837 ) 8,288 Lab equipment 291,235 (31,572 ) 42,375 (101,047 ) 232,564 646,306 (101,900 ) 49,192 (379,993 ) 315,505 During the three-month period ended November 30, 2022, $2,438 of depreciation was included in cost of goods sold.

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	3 Months Ended
	Nov. 30, 2022
Accounts Payable and Accrued Liabilities
Accounts Payable and Accrued Liabilities	13. Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities at November 30, 2022 and August 31, 2022 consist of the following: November 30, August 31, 2022 2022 $ $ Accounts Payable Trades payable 173,678 57,150 Sales tax payable 11,011 31,303 Accrued Liabilities Trades payable 57,202 62,996 Balance 241,891 151,449

Revenues

Revenues	3 Months Ended
	Nov. 30, 2022
Revenues
Revenues	14. Revenues A breakdown of our revenues by type for the three months ended November 30, 2022 and 2021 are as follows: Three Months Ended November 30, 2022 November 30, 2021 $ $ B2B sales 29,100 7,000 Licensing 63,435 - Other 8,941 6,880 Total 101,476 13,880 During the period ended November 30, 2022, the Company recognized B2B product revenues of $29,100 (2021 - $7,000) that relate to sales of our intermediate products for use by B2B customers in their products. Licensing revenue consist of IP licensing fees for transfer of the DehydraTECH technology in line with definitive agreements and also includes royalty fees. The Company recognized $63,435 (2021 - $Nil) in licensing revenue in the same period.

Common Shares and Warrants

Common Shares and Warrants	3 Months Ended
	Nov. 30, 2022
Common Shares and Warrants
Common Shares and Warrants	15. Common Shares and Warrants The fair value of share purchase warrants granted was estimated as of the date of the grant by using the Black-Scholes option pricing model. During the quarter ended November 30, 2022, the Company issued no warrants. A continuity schedule for warrants is presented below: Number of Warrants Weighted Average Exercise Price $ Balance August 31, 2022 2,421,983 8.04 Cancelled/expired (7,500 ) 24.00 Balance November 30, 2022 2,414,483 7.99 A summary of warrants outstanding as of November 30, 2022, is presented below: # of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 60,798 1.96-2.00 years 36.00 317,190 2.43 years 10.50 116,667 1.38-2.29 years 9.00 200,000 1.38 years 7.00 1,719,828 3.13 years 6.58 2,414,483 2.78 years 7.99

Stock Options

Stock Options	3 Months Ended
	Nov. 30, 2022
Stock Options
Stock Options	16. Stock Options The Company has established the Equity Incentive Plan whereby the board of directors may, from time to time, grant up to 510,433 stock options to directors, officers, employees, and consultants. Stock options granted must be exercised within five years from the date of grant or such lesser period as determined by the Company’s board of directors. The exercise price of an option is equal to or greater than the closing market price of the Company’s common shares on the day preceding the date of grant. The vesting terms of each grant are set by the board of directors. The Company granted the following options during the quarter ended November 30, 2022: Quantity Exercise Price $ Life (Years) 3,400 3.04 5 41,200 1.96 5 44,600 2.04 5 A continuity schedule for stock options is presented below: Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value $ Balance August 31, 2021 206,170 8.90 Cancelled/expired (3,334 ) 9.60 Granted 222,000 4.21 Balance August 31, 2022 424,836 6.45 3.69 5,175 Granted 44,600 2.04 Balance November 30, 2022 (granted) 469,436 5.35 3.91 46,375 Balance November 30, 2022 (exercisable) 441,963 5.41 3.90 41,200 The fair value of share purchase options granted were estimated as of the date of the grant by using the Black-Scholes option pricing model with the following assumptions: November 30, 2022 Expected volatility 99%-105 % Risk-free interest rate 3.30-4.12 % Expected life 5 years Dividend yield 0 % Estimated fair value per option $1.60 - $2.58

Commitments Significant Contrac

Commitments Significant Contracts and Contingencies	3 Months Ended
	Nov. 30, 2022
Commitments Significant Contracts and Contingencies
Commitments, Significant Contracts and Contingencies	17. Commitments, Significant Contracts and Contingencies Right of Use Assets - Operating Lease The Corporate office and R&D lab space located in Kelowna, British Columbia, Canada is leased until November 15, 2023, with a five-year renewal option. In addition to minimum lease payments, the lease requires us to pay property taxes and operating costs which are subject to annual adjustments. November 30, 2022 August 31, 2022 $ $ Right of use assets - operating leases 52,444 91,041 Amortization (10,104 ) (38,597 ) Total lease assets 42,340 52,444 Liabilities: 49,989 89,393 Lease payments (11,204 ) (44,600 ) Interest accretion 844 5,195 Total lease liabilities 39,629 49,988 Operating lease cost 52,444 52,444 Operating cash flows for lease 11,204 44,599 Remaining lease term 0.9 Years 1.17 Years Discount rate 7.25 % 7.25 % Pursuant to the terms of the Company’s lease agreements in effect, the following table summarizes the Company’s maturities of operating lease liabilities as of November 30, 2022: Fiscal 2023 33,611 Fiscal 2024 7,470 Thereafter - Total lease payments 41,081 Less: imputed interest (1,452 ) Present value of operating lease liabilities 39,629 Less: current obligations under leases (39,629 ) Total -

Segment Information

Segment Information	3 Months Ended
	Nov. 30, 2022
Segment Information
Segment Information	18. Segment Information The Company’s operations involve the development and usage, including licensing, of its proprietary DehydraTECH Technology. Lexaria is centrally managed and its chief operating decision makers, being the president and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health consumer products and technology licensing to make operational decisions and to assess the performance of the Company. The Company has identified two reportable segments: Intellectual Property and Products. Licensing revenues are significantly concentrated on one licensee. Three Months Ended November 30, 2022 IP Licensing $ B2B $ Corporate $ Consolidated Total $ Revenue 63,435 29,100 8,941 101,476 Cost of goods sold - (15,795 ) - (15,795 ) Operating expenses (707,034 ) (10,992 ) (1,136,961 ) (1,854,987 ) Segment income (loss) (643,599 ) 2,313 (1,128,020 ) (1,769,306 ) Total assets 118,096 75,723 6,019,661 6,213,480 Three Months Ended November 30, 2021 IP Licensing $ Products $ Corporate $ Consolidated Total $ External revenue - 7,000 6,880 13,880 Cost of goods sold - (5,570 ) - (5,570 ) Operating expenses (837,750 ) (77,002 ) (1,097,040 ) (2,011,792 ) Segment loss (837,750 ) (75,572 ) (1,090,160 ) (2,003,482 ) Total assets 724,665 116,060 10,905,217 11,745,942 Capital Asset by Region Cost US Addition US Net Balance US Cost Canada Net Balance Canada Total Net Balance Three Months Ended November 30, 2022 $ $ $ $ $ $ Leasehold Improvements - - - 259,981 51,786 51,786 Computers - - - 70,781 8,174 8,174 Furniture & Fixtures - - - 31,126 6,684 6,684 Lab Equipment 140,487 20,500 116,553 193,185 128,024 244,577 140,487 20,500 116,553 555,073 194,668 311,221 Capital Asset by Region Cost US Addition US Net Balance US Cost Canada Addition Canada Net Balance Canada Total Net Balance Year Ended August 31, 2022 $ $ $ $ $ $ $ Leasehold Improvements - - - 259,981 - 65,296 65,296 Computers - - - 63,964 6,817 9,357 9,357 Furniture & Fixtures - - - 31,126 - 8,288 8,288 Lab Equipment 98,050 42,375 100,031 193,185 - 132,533 232,564 98,050 42,375 100,031 548,256 6,817 215,474 315,505

Subsequent Events

Subsequent Events	3 Months Ended
	Nov. 30, 2022
Subsequent Events
Subsequent Events	19. Subsequent Events N/A

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Nov. 30, 2022
Marketable Securities
Schedule of marketable securities	Cost Basis $ Unrealized Gains $ Unrealized Losses $ Fair Value $ August 31, 2021 1,037,025 16,243 (219,427 ) 833,841 Common stock 278,107 118,196 (882,809 ) (486,506 ) August 31, 2022 1,315,132 134,439 (1,102,236 ) 347,335 Common stock - - (77,628 ) (77,628 ) November 30, 2022 1,315,132 134,439 (1,179,864 ) 269,707

Accounts Receivables (Tables)

Accounts Receivables (Tables)	3 Months Ended
	Nov. 30, 2022
Accounts Receivables
Schedule of accounts receivables	November 30, August 31, 2022 2022 $ $ Trade and deposits 137,041 80,374 Territory license fees 100,683 37,248 Sales tax 48,598 84,162 286,322 201,784

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Nov. 30, 2022
Inventory
Schedule of Inventory	November 30, August 31, 2022 2022 $ $ Raw materials 9,936 38,418

Prepaid Expenses and Deposits (

Prepaid Expenses and Deposits (Tables)	3 Months Ended
	Nov. 30, 2022
Prepaid Expenses and Deposits (Tables)
Schedule of Prepaid Expenses and Deposits	November 30, August 31, 2022 2022 $ $ Advertising & conferences 74,656 359,863 Legal fees 25,000 25,000 License, filing fees, dues 3,750 15,000 Office & insurance 60,901 80,863 Capital financing 96,035 96,035 260,342 576,761

Intellectual Property, net (Tab

Intellectual Property, net (Tables)	3 Months Ended
	Nov. 30, 2022
Intellectual Property, net
Schedule of patents	November 30, August 31, 2022 2022 $ $ Balance – beginning 488,462 364,623 Addition 14,342 131,448 Amortization (2,255 ) (7,609 ) Balance – ending 500,549 488,462 Patents are amortized over their 20 year legal life.

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	3 Months Ended
	Nov. 30, 2022
Property and Equipment, net
Schedule of property, plant & equipment	Three Months Ended November 30, 2022 Cost Period Amortization Additions Accumulated Amortization Net Balance November 30, 2022 $ $ $ $ $ Leasehold improvements 259,981 (13,509 ) - (208,195 ) 51,786 Computers 70,781 (1,183 ) - (62,607 ) 8,174 Furniture fixtures & equipment 31,126 (1,604 ) - (24,442 ) 6,684 Lab equipment 333,675 (8,616 ) 20,500 (109,598 ) 244,577 695,563 (24,912 ) 20,500 (404,842 ) 311,221 Year Ended August 31, 2022 Cost Period Amortization Disposal Accumulated Amortization Net Balance August 31, 2022 $ $ $ $ $ Leasehold improvements 259,981 (54,037 ) - (194,685 ) 65,296 Computers 63,964 (9,874 ) 6,817 (61,424 ) 9,357 Furniture fixtures & equipment 31,126 (6,417 ) - (22,837 ) 8,288 Lab equipment 291,235 (31,572 ) 42,375 (101,047 ) 232,564 646,306 (101,900 ) 49,192 (379,993 ) 315,505

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	3 Months Ended
	Nov. 30, 2022
Accounts Payable and Accrued Liabilities
Schedule of accounts payable and accrued liabilities	November 30, August 31, 2022 2022 $ $ Accounts Payable Trades payable 173,678 57,150 Sales tax payable 11,011 31,303 Accrued Liabilities Trades payable 57,202 62,996 Balance 241,891 151,449

Revenues (Tables)

Revenues (Tables)	3 Months Ended
	Nov. 30, 2022
Revenues
Schedule of revenue	Three Months Ended November 30, 2022 November 30, 2021 $ $ B2B sales 29,100 7,000 Licensing 63,435 - Other 8,941 6,880 Total 101,476 13,880

Common Shares and Warrants (Tab

Common Shares and Warrants (Tables)	3 Months Ended
	Nov. 30, 2022
Common Shares and Warrants
Schedule of warrant	Number of Warrants Weighted Average Exercise Price $ Balance August 31, 2022 2,421,983 8.04 Cancelled/expired (7,500 ) 24.00 Balance November 30, 2022 2,414,483 7.99
Schedule of warrants outstanding	# of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 60,798 1.96-2.00 years 36.00 317,190 2.43 years 10.50 116,667 1.38-2.29 years 9.00 200,000 1.38 years 7.00 1,719,828 3.13 years 6.58 2,414,483 2.78 years 7.99

Stock Options (Tables)

Stock Options (Tables)	3 Months Ended
	Nov. 30, 2022
Stock Options
Summary of continuity schedule of stock options	Quantity Exercise Price $ Life (Years) 3,400 3.04 5 41,200 1.96 5 44,600 2.04 5
Schedule of stock options activity	Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value $ Balance August 31, 2021 206,170 8.90 Cancelled/expired (3,334 ) 9.60 Granted 222,000 4.21 Balance August 31, 2022 424,836 6.45 3.69 5,175 Granted 44,600 2.04 Balance November 30, 2022 (granted) 469,436 5.35 3.91 46,375 Balance November 30, 2022 (exercisable) 441,963 5.41 3.90 41,200
Schedule of fair value of options granted	November 30, 2022 Expected volatility 99%-105 % Risk-free interest rate 3.30-4.12 % Expected life 5 years Dividend yield 0 % Estimated fair value per option $1.60 - $2.58

Commitments Significant Contr_2

Commitments Significant Contracts and Contingencies (Tables)	3 Months Ended
	Nov. 30, 2022
Commitments Significant Contracts and Contingencies
Schedule of operating lease liabilities	Fiscal 2023 33,611 Fiscal 2024 7,470 Thereafter - Total lease payments 41,081 Less: imputed interest (1,452 ) Present value of operating lease liabilities 39,629 Less: current obligations under leases (39,629 ) Total -
Schedule of maturities of operating lease liabilities	November 30, 2022 August 31, 2022 $ $ Right of use assets - operating leases 52,444 91,041 Amortization (10,104 ) (38,597 ) Total lease assets 42,340 52,444 Liabilities: 49,989 89,393 Lease payments (11,204 ) (44,600 ) Interest accretion 844 5,195 Total lease liabilities 39,629 49,988 Operating lease cost 52,444 52,444 Operating cash flows for lease 11,204 44,599 Remaining lease term 0.9 Years 1.17 Years Discount rate 7.25 % 7.25 %

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Nov. 30, 2022
Segment Information
Schedule of profit or loss and total assets for each reportable segment	Three Months Ended November 30, 2022 IP Licensing $ B2B $ Corporate $ Consolidated Total $ Revenue 63,435 29,100 8,941 101,476 Cost of goods sold - (15,795 ) - (15,795 ) Operating expenses (707,034 ) (10,992 ) (1,136,961 ) (1,854,987 ) Segment income (loss) (643,599 ) 2,313 (1,128,020 ) (1,769,306 ) Total assets 118,096 75,723 6,019,661 6,213,480 Three Months Ended November 30, 2021 IP Licensing $ Products $ Corporate $ Consolidated Total $ External revenue - 7,000 6,880 13,880 Cost of goods sold - (5,570 ) - (5,570 ) Operating expenses (837,750 ) (77,002 ) (1,097,040 ) (2,011,792 ) Segment loss (837,750 ) (75,572 ) (1,090,160 ) (2,003,482 ) Total assets 724,665 116,060 10,905,217 11,745,942
Schedule of capital asset by region	Capital Asset by Region Cost US Addition US Net Balance US Cost Canada Net Balance Canada Total Net Balance Three Months Ended November 30, 2022 $ $ $ $ $ $ Leasehold Improvements - - - 259,981 51,786 51,786 Computers - - - 70,781 8,174 8,174 Furniture & Fixtures - - - 31,126 6,684 6,684 Lab Equipment 140,487 20,500 116,553 193,185 128,024 244,577 140,487 20,500 116,553 555,073 194,668 311,221 Capital Asset by Region Cost US Addition US Net Balance US Cost Canada Addition Canada Net Balance Canada Total Net Balance Year Ended August 31, 2022 $ $ $ $ $ $ $ Leasehold Improvements - - - 259,981 - 65,296 65,296 Computers - - - 63,964 6,817 9,357 9,357 Furniture & Fixtures - - - 31,126 - 8,288 8,288 Lab Equipment 98,050 42,375 100,031 193,185 - 132,533 232,564 98,050 42,375 100,031 548,256 6,817 215,474 315,505

Nature of Business (Detail Narr

Nature of Business (Detail Narrative) - Emergency Business Account Loan Program [Member] - USD ($)		3 Months Ended	12 Months Ended
	Jan. 12, 2021	Aug. 31, 2021	Aug. 31, 2022	Aug. 31, 2021	Aug. 31, 2020	Nov. 30, 2022
Accumulated deficit						$ 40,900,000
Loss attributable to shareholders			$ 7,400,000	$ 4,200,000	$ 4,100,000
Proceeds from underwritten public offering	$ 9,471,497
Proceeds from exercise of warrants		$ 4,015,043
Cash and cash equivalents			$ 4,500,000

Basis of Consolidation (Detail

Basis of Consolidation (Detail Narrative)	Nov. 30, 2022
Lexaria Nicotine L L C
Equity interest percentage	83.33%
Altria Ventures Inc
Equity interest percentage	16.66%

Marketable Securities (Details)

Marketable Securities (Details) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2022	Aug. 31, 2022	Aug. 31, 2021
Total [Member]
Cost Basis	$ 1,315,132	$ 1,315,132	$ 1,037,025
Unrealized Gains	134,439	134,439	16,243
Unrealized Losses	(1,179,864)	(1,102,236)	(219,427)
Fair Value	269,707	347,335	$ 833,841
Common Stock [Member]
Cost Basis	0	278,107
Unrealized Gains	0	118,196
Unrealized Losses	(77,628)	(882,809)
Fair Value	$ (77,628)	$ (486,506)

Accounts Receivables (Details)

Accounts Receivables (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Account receivable	$ 286,322	$ 201,784
Sales tax [Member]
Account receivable	48,598	84,162
Territory license fee [Member]
Account receivable	100,683	37,248
Trade and deposits [Member]
Account receivable	$ 137,041	$ 80,374

Inventory (Details)

Inventory (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Inventory
Raw materials	$ 9,936	$ 38,418

Inventory (Details Narrative)

Inventory (Details Narrative)	3 Months Ended
	Nov. 30, 2022 USD ($)
Inventory (Details Narrative)
Inventory	$ 25,243

Prepaid Expenses and Deposits_2

Prepaid Expenses and Deposits (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Prepaid Expenses and Deposits
Advertising and Conferences	$ 74,656	$ 359,863
Legal fees	25,000	25,000
Licence, filing fees, dues	3,750	15,000
Office and insurance	60,901	80,863
Capital Financing	96,035	96,035
Prepaid expenses	$ 260,342	$ 576,761

Intellectual Property, net (Det

Intellectual Property, net (Details)	3 Months Ended
	Nov. 30, 2022
Patent Two [Member]
Issued patent	US 9,839,612 B2
Patent certificate grant date Descriptions	12/12/2017
Patent Three [Member]
Issued patent	US 9,972,680 B2
Patent certificate grant date Descriptions	05/15/2018
Patent Four [Member]
Issued patent	US 9,974,739 B2
Patent certificate grant date Descriptions	05/22/2018
Patent Five [Member]
Issued patent	US 10,084,044 B2
Patent certificate grant date Descriptions	09/25/2018
Patent Six [Member]
Issued patent	US 10,103,225 B2
Patent certificate grant date Descriptions	10/16/2018
Patent Seven [Member]
Issued patent	US 10,381,440
Patent certificate grant date Descriptions	08/13/2019
Patent Eight [Member]
Issued patent	US 10,374,036
Patent certificate grant date Descriptions	08/06/2019
Patent Nine [Member]
Issued patent	US 10,756,180
Patent certificate grant date Descriptions	08/25/2020
Patent ten [Member]
Issued patent	US 11,311,559
Patent certificate grant date Descriptions	04/26/2022
Patent One [Member]
Issued patent	US 9,474,725 B1
Patent certificate grant date Descriptions	10/25/2016

Intellectual Property, net (D_2

Intellectual Property, net (Details 1) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2022	Aug. 30, 2022
Intellectual Property, net
Balance- beginning	$ 488,462	$ 364,623
Addition	14,342	131,448
Amortization	(2,255)	(7,609)
Balance - ending	$ 500,549	$ 488,462

Intellectual Property, net (D_3

Intellectual Property, net (Details Narrative)	3 Months Ended
	Nov. 30, 2022
Intellectual Property, net
Useful life of patents	20 years

Property and Equipment, net (De

Property and Equipment, net (Details) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2022	Aug. 31, 2022
Costs	$ 695,563	$ 646,306
Additions	20,500	49,192
Accumulated amortization	(404,842)	(379,993)
Balance-end of the period	311,221	315,505
Period Amortization [Member]
Accumulated amortization	(24,912)	(101,900)
Leasehold Improvements [Member]
Costs	259,981	259,981
Additions	0
Accumulated amortization	(208,195)	(194,685)
Balance-end of the period	51,786	65,296
Disposal		0
Leasehold Improvements [Member] | Period Amortization [Member]
Accumulated amortization	(13,509)	(54,037)
Computer [Member]
Costs	70,781	63,964
Additions	0
Accumulated amortization	(62,607)	(61,424)
Balance-end of the period	8,174	9,357
Disposal		(6,817)
Computer [Member] | Period Amortization [Member]
Accumulated amortization	(1,183)	(9,874)
Furniture Fixtures Equipment [Member]
Costs	31,126	31,126
Additions	0
Accumulated amortization	(24,442)	(22,837)
Balance-end of the period	6,684	8,288
Disposal		0
Furniture Fixtures Equipment [Member] | Period Amortization [Member]
Accumulated amortization	(1,604)	(6,417)
Lab Equipment [Member]
Costs	333,675	291,235
Additions	20,500
Accumulated amortization	(109,598)	(101,047)
Balance-end of the period	244,577	232,564
Disposal		(42,375)
Lab Equipment [Member] | Period Amortization [Member]
Accumulated amortization	$ (8,616)	$ (31,572)

Property and Equipment, net (_2

Property and Equipment, net (Details Narrative)	3 Months Ended
	Nov. 30, 2022 USD ($)
Property and Equipment, net (Details)
Amortization	$ 2,438

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Accounts payable and accrued liabilities	$ 241,891	$ 151,449
Accrued Liabilities [Member]
Trades payable	57,202	62,996
Accounts Payable [Member]
Trades payable	173,678	57,150
Sales tax payable	$ 11,011	$ 31,303

Revenues (Details)

Revenues (Details) - USD ($)	3 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Income from operations	$ 101,476	$ 13,880
Licensing [Member]
Income from operations	63,435	0
Other [Member]
Income from operations	8,941	6,880
B2B [Member]
Income from operations	$ 29,100	$ 7,000

Revenues (Details Narrative)

Revenues (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2022	Aug. 31, 2021
Estimates and Judgments
Product revenues	$ 29,100,000	$ 7,000,000
licensing usage	$ 63,435,000	$ 0

Common Shares and Warrants (Det

Common Shares and Warrants (Details)	3 Months Ended
	Nov. 30, 2022 $ / shares shares
Common Shares and Warrants
Number of Warrants, Beginning Balance | shares	2,421,983
Number of Warrants, Cancelled/Expired | shares	(7,500)
Number of Warrants, Ending Balance | shares	2,414,483
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 8.04
Weighted Average Exercise Price, Cancelled/Expired | $ / shares	24
Weighted Average Exercise Price, Ending Balances | $ / shares	$ 7.99

Common Shares and Warrants (D_2

Common Shares and Warrants (Details 1) - $ / shares	3 Months Ended
	Nov. 30, 2022	Aug. 31, 2022	Feb. 28, 2022	Nov. 30, 2021	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2018
Number of Warrants	2,414,483	2,421,983	2,421,983	2,421,983	2,447,275	471,608	3,286,274
Weighted Average Exercise Price	$ 7.99
Weighted Average Exercise Price	$ 2.78
Warrants 1
Number of Warrants	60,798
Weighted Average Exercise Price	$ 36
Warrants 1 | Minimum
Weighted Average Remaining Contractual Life	1 year 11 months 15 days
Warrants 1 | Maximum
Weighted Average Remaining Contractual Life	2 years
Warrants 2
Number of Warrants	317,190
Weighted Average Exercise Price	$ 10.50
Weighted Average Remaining Contractual Life	2 years 5 months 4 days
Warrants 5
Number of Warrants	1,719,828
Weighted Average Exercise Price	$ 6.58
Weighted Average Remaining Contractual Life	3 years 1 month 17 days
Warrants 3
Number of Warrants	116,667
Weighted Average Exercise Price	$ 9
Warrants 3 | Minimum
Weighted Average Remaining Contractual Life	1 year 4 months 17 days
Warrants 3 | Maximum
Weighted Average Remaining Contractual Life	2 years 3 months 14 days
Warrants 4
Number of Warrants	200,000
Weighted Average Exercise Price	$ 7
Weighted Average Remaining Contractual Life	1 year 4 months 17 days

Stock Options (Details)

Stock Options (Details) - $ / shares	3 Months Ended	12 Months Ended
	Nov. 30, 2022	Aug. 31, 2022
Exercise price	$ 2.04	$ 4.21
Stock Options 2
Exercise price	$ 1.96
Life (Years)	5 years
Quantity	41,200
Stock Options 3
Exercise price	$ 2.04
Life (Years)	5 years
Quantity	44,600
Stock Options 1
Exercise price	$ 3.04
Life (Years)	5 years
Quantity	3,400

Stock Options (Details 1)

Stock Options (Details 1) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2022	Aug. 31, 2022	Aug. 31, 2021
Stock Options
Beginning Balance, Outstanding		206,170
Expired/Cancelled		(3,334)
Granted	44,600	222,000
Ending Balance, Outstanding	469,436	424,836
Ending Balance, Exercisable	441,963
Weighted average exercise price, Expired/Cancelled		$ 9.60
Weighted average exercise price, Granted	$ 2.04	4.21
Weighted average exercise price, Beginning Balance, Outstanding	5.35	$ 6.45	$ 8.90
Weighted average exercise price, exercisable	$ 5.41
Weighted Average Remaining Contractual Term, Outstanding (Years)	3 years 10 months 28 days	3 years 8 months 8 days
Weighted Average Remaining Contractual Term, Exercisable (Years)	3 years 10 months 24 days
Aggregate intrinsic value, granted	$ 5,175
Aggregate Intrinsic Value, Exercisable	41,200
Aggregate Intrinsic Value, Outstanding	$ 46,375

Stock Options (Details 2)

Stock Options (Details 2)	3 Months Ended
	Nov. 30, 2022 $ / shares
Expected life	5 years
Dividend yield	0%
Estimated fair value per option Minimum	$ 1.60
Estimated fair value per option Maximum	$ 2.58
Minimum Member
Expected volatility Minimum	99%
Risk-free interest rate Minimum	3.30%
Maximum
Expected volatility Minimum	105%
Risk-free interest rate Minimum	4.12%

Stock Options (Detail Narrative

Stock Options (Detail Narrative)	3 Months Ended
	Nov. 30, 2022
Stock Options
Description of incentives plan	The Company has established the Equity Incentive Plan whereby the board of directors may, from time to time, grant up to 510,433 stock options to directors, officers, employees, and consultants

Commitments Significant Contr_3

Commitments Significant Contracts and Contingencies (Details) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2022	Aug. 31, 2022
Commitments Significant Contracts and Contingencies
Right of use assets - operating leases	$ 52,444	$ 91,041
Amortization	10,104	38,597
Total lease assets	42,340	52,444
Liabilities operating lease	49,989	89,393
Lease payments	(11,204)	(44,600)
Interest accretion	844	5,195
Total lease liabilities	39,629	49,988
Operating lease cost	52,444	52,444
Operating cash flows for lease	$ 11,204	$ 44,599
Remaining lease term	10 months 24 days	1 year 2 months 1 day
Discount rate	7.25%	7.25%

Commitments Significant Contr_4

Commitments Significant Contracts and Contingencies (Details 1)	Nov. 30, 2022 USD ($)
Commitments Significant Contracts and Contingencies
Fiscal 2023	$ 33,611
Fiscal 2024	7,470
Thereafter	0
Total lease payments	41,081
Less: imputed interest	(1,452)
Present value of operating lease liabilities	39,629
Less: current obligations under leases	(39,629)
Total	$ 0

Segment Information (Details)

Segment Information (Details) - USD ($)	3 Months Ended
	Nov. 30, 2022	Nov. 30, 2021	Aug. 31, 2022
Revenue	$ 101,476	$ 13,880
Cost of goods sold	15,795	5,570
Operating expense	(1,854,987)	(2,011,792)
Segment income (loss)	(1,769,306)	(2,003,482)
Total assets	6,213,480	11,745,942	$ 7,833,927
Products
Revenue		7,000
Cost of goods sold		5,570
Operating expense		(77,002)
Total assets		116,060
Segment loss		(75,572)
IP Licensing
Revenue	63,435	0
Cost of goods sold	0	0
Operating expense	(707,034)	(837,750)
Segment income (loss)	(643,599)	(837,750)
Total assets	118,096	724,665
Corporate
Revenue	8,941	6,880
Cost of goods sold	0	0
Operating expense	(1,136,961)	(1,097,040)
Segment income (loss)	(1,128,020)	(1,090,160)
Total assets	6,019,661	$ 10,905,217
B2B [Member]
Revenue	29,100
Cost of goods sold	15,795
Operating expense	(10,992)
Segment income (loss)	2,313
Total assets	$ 75,723

Segment Information (Details 1)

Segment Information (Details 1) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Net Balance	$ 311,221	$ 315,505
Net Balance	311,221	315,505
Canada [Member]
Net Balance	194,668	215,474
Cost	555,073	548,256
Addition		6,817
US [Member]
Net Balance	116,553	100,031
Cost	140,487	98,050
Addition	20,500	42,375
Leasehold Improvements [Member]
Net Balance	51,786	65,296
Leasehold Improvements [Member] | Canada [Member]
Net Balance	51,786	65,296
Cost	259,981	259,981
Addition		0
Leasehold Improvements [Member] | US [Member]
Net Balance	0	0
Cost	0	0
Addition	0	0
Furniture Fixtures Equipment [Member]
Net Balance	6,684	8,288
Furniture Fixtures Equipment [Member] | Canada [Member]
Net Balance	6,684	8,288
Cost	31,126	31,126
Addition		0
Furniture Fixtures Equipment [Member] | US [Member]
Net Balance	0	0
Cost	0	0
Addition	0	0
Lab Equipment [Member]
Net Balance	244,577	232,564
Lab Equipment [Member] | Canada [Member]
Net Balance	128,024	132,533
Cost	193,185	193,185
Addition		0
Lab Equipment [Member] | US [Member]
Net Balance	116,553	100,031
Cost	140,487	98,050
Addition	20,500	42,375
Computer Equipment [Member]
Net Balance	8,174	9,357
Computer Equipment [Member] | Canada [Member]
Net Balance	8,174	9,357
Cost	70,781	63,964
Addition		6,817
Computer Equipment [Member] | US [Member]
Net Balance	0	0
Cost	0	0
Addition	$ 0	$ 0